


08 141914  
1/8/12(3-methyl-TTNCB)  
STANDARDIZED AGONIST DOSE RESPONSE

(ALL TRANS RETINOIC ACID)  
STANDARDIZED AGONIST DOSE RESPONSE






Fig. 2

RECEPTOR	
—○—	pRSbRAR-alpha (wt)
—△—	pRSbRAR-beta (wt)
—×—	pRSbRAR-gamma (wt)
—○—	pRSbRXR-alpha (wt)
—×—	pRSmRXR-beta (wt)
—□—	pRSmRXR-gamma (wt)


(9CIS RETINOIC ACID)  
STANDARDIZED AGONIST DOSE RESPONSE



(3-methyl-TTNEB)  
STANDARDIZED AGONIST DOSE RESPONSE



(3-bromo-TTNEB)  
STANDARDIZED AGONIST DOSE RESPONSE



(3-methyl-TTNCHBP)  
STANDARDIZED AGONIST DOSE RESPONSE






Fig. 6



(3-methyl-TTNEHBP)  
STANDARDIZED AGONIST DOSE RESPONSE






Fig. 8






Fig. 9

EFFECT OF RETINOIDS ON RAT HDL CHOLESTEROL




Figure 10

### Myeloma RPMI-8226 Cell Proliferation




Figure 12




Figure 11